[go: up one dir, main page]

PL1686997T3 - Inhibitory zmutowanej formy KIT - Google Patents

Inhibitory zmutowanej formy KIT

Info

Publication number
PL1686997T3
PL1686997T3 PL04818795T PL04818795T PL1686997T3 PL 1686997 T3 PL1686997 T3 PL 1686997T3 PL 04818795 T PL04818795 T PL 04818795T PL 04818795 T PL04818795 T PL 04818795T PL 1686997 T3 PL1686997 T3 PL 1686997T3
Authority
PL
Poland
Prior art keywords
kit
inhibitors
mutant form
mutant
administered
Prior art date
Application number
PL04818795T
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1686997T3 publication Critical patent/PL1686997T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL04818795T 2003-11-18 2004-11-17 Inhibitory zmutowanej formy KIT PL1686997T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
PCT/EP2004/013045 WO2005049032A1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit
EP04818795A EP1686997B1 (en) 2003-11-18 2004-11-17 Inhibitors of the mutant form of kit

Publications (1)

Publication Number Publication Date
PL1686997T3 true PL1686997T3 (pl) 2009-09-30

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04818795T PL1686997T3 (pl) 2003-11-18 2004-11-17 Inhibitory zmutowanej formy KIT

Country Status (28)

Country Link
US (3) US8017621B2 (pl)
EP (2) EP1686997B1 (pl)
JP (3) JP4762150B2 (pl)
KR (1) KR101153647B1 (pl)
CN (3) CN1882344A (pl)
AT (1) ATE428426T1 (pl)
AU (1) AU2004290902B2 (pl)
BR (1) BRPI0416680A (pl)
CA (1) CA2546189C (pl)
CY (1) CY1110354T1 (pl)
DE (1) DE602004020654D1 (pl)
DK (1) DK1686997T3 (pl)
ES (1) ES2324917T3 (pl)
HK (1) HK1093680A1 (pl)
HR (1) HRP20090390T1 (pl)
IL (2) IL175578A (pl)
MA (1) MA28176A1 (pl)
MX (1) MXPA06005598A (pl)
NO (1) NO20062694L (pl)
NZ (1) NZ547195A (pl)
PL (1) PL1686997T3 (pl)
PT (1) PT1686997E (pl)
RU (2) RU2362562C2 (pl)
SG (1) SG139747A1 (pl)
SI (1) SI1686997T1 (pl)
TN (1) TNSN06138A1 (pl)
WO (1) WO2005049032A1 (pl)
ZA (1) ZA200603905B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
CN101010082A (zh) * 2004-08-31 2007-08-01 诺瓦提斯公司 米哚妥林用于治疗胃肠道基质瘤的用途
EP1879584B1 (en) * 2005-05-02 2016-06-22 Novartis AG Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
CN103638028A (zh) 2005-05-02 2014-03-19 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CN101267837B (zh) * 2005-07-20 2010-12-15 彼得·瓦伦特 用于治疗系统性肥大细胞增生症的组合物
PT1959957E (pt) * 2005-12-06 2012-10-29 Novartis Ag Derivados de pirimidilaminobenzamida para o tratamento de neurofibromatose
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
PT2237783E (pt) * 2008-01-23 2014-12-23 Novartis Ag Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib
WO2015082887A2 (en) * 2013-12-02 2015-06-11 Bergenbio As Use of kinase inhibitors
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (zh) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 用于检测c-kit基因突变的引物、探针及试剂盒
CA3102381A1 (en) 2018-06-15 2019-12-19 Handa Oncology, Llc Kinase inhibitor salts and compositions thereof
TW202039862A (zh) * 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pl) 1992-04-03 1994-06-21 Ciba Geigy Ag
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
AU7821398A (en) 1997-06-06 1998-12-21 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CN1282253A (zh) 1997-11-13 2001-01-31 海斯塔泰克有限责任公司 小肽和用于治疗哮喘和炎症的方法
US20040157855A1 (en) * 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
JP2005503361A (ja) 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
EP1483401A1 (en) 2002-03-13 2004-12-08 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
EP1667719B1 (en) * 2003-09-19 2010-11-24 Novartis AG Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
CN103638028A (zh) 2005-05-02 2014-03-19 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
ZA200603905B (en) 2008-11-26
CN101693031A (zh) 2010-04-14
RU2006121447A (ru) 2008-01-10
BRPI0416680A (pt) 2007-02-13
IL229124A0 (en) 2013-12-31
ATE428426T1 (de) 2009-05-15
JP2011121973A (ja) 2011-06-23
CA2546189A1 (en) 2005-06-02
RU2009110449A (ru) 2010-09-27
NZ547195A (en) 2010-06-25
US20120157441A1 (en) 2012-06-21
PT1686997E (pt) 2009-07-17
MA28176A1 (fr) 2006-09-01
JP2013241438A (ja) 2013-12-05
AU2004290902B2 (en) 2008-09-25
DK1686997T3 (da) 2009-07-27
RU2362562C2 (ru) 2009-07-27
JP2007511567A (ja) 2007-05-10
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
EP1686997A1 (en) 2006-08-09
NO20062694L (no) 2006-06-12
IL175578A0 (en) 2008-04-13
MXPA06005598A (es) 2006-08-11
CN1882344A (zh) 2006-12-20
CN102274230B (zh) 2015-07-01
SI1686997T1 (sl) 2009-08-31
HRP20090390T1 (hr) 2009-08-31
EP1917965A1 (en) 2008-05-07
EP1686997B1 (en) 2009-04-15
US8017621B2 (en) 2011-09-13
KR101153647B1 (ko) 2012-06-18
DE602004020654D1 (de) 2009-05-28
TNSN06138A1 (fr) 2007-11-15
US20100179179A1 (en) 2010-07-15
AU2004290902A1 (en) 2005-06-02
US20070213317A1 (en) 2007-09-13
CA2546189C (en) 2013-04-23
WO2005049032A1 (en) 2005-06-02
RU2405553C1 (ru) 2010-12-10
CN102274230A (zh) 2011-12-14
HK1093680A1 (en) 2007-03-09
US8124611B2 (en) 2012-02-28
KR20060101761A (ko) 2006-09-26
JP4762150B2 (ja) 2011-08-31
SG139747A1 (en) 2008-02-29
IL175578A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
IL229124A0 (en) Inhibitors with a mutant form of kit
GB0223040D0 (en) Therapeutic compounds
NO20034056D0 (no) Proliferative sykdommer
PL1983000T3 (pl) Sposób leczenia stwardnienia rozsianego przez hamowanie aktywności IL-17
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
SI1423381T1 (sl) Inhibitorji 17-beta-hidroksisteroidne dehidrogenaze tipa 3 za zdravljenje androgensko odvisnih bolezni
NO20065117L (no) Sammensetning omfattende en JNK inhibitor og syklosporin.
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
DE60329515D1 (de) Analoga und prodrugs von buprenorphin
TW200510397A (en) Conjugated complement cascade inhibitors
NO20044459L (no) Anvendelse av IL-18-inhibitorer for behandlingen og/eller forebyggingen av perifere vaskulaere sykdomrner
WO2005046657A3 (en) Use of an inhibitor of csf-1 activity for the treatment of inflammatory bowel disease
MY146509A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
AU2003214211A1 (en) Enhancement of iron chelation therapy
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
AU2003290799A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
GEP20094699B (en) THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ß-INTERFERON
WO2003086309A3 (en) NF-κB INHIBITORS
ZA200503703B (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
MXPA04011019A (es) Combinacion de un inhibidor de la bomba de protones y un agente respiratorio, para el tratamiento de trastornos de las vias respiratorias.
TW200605895A (en) Combination of a selective noradrenaline reuptake inhibitor and a PDEV inhibitor